Диссертация (1140142), страница 18
Текст из файла (страница 18)
Dermatol. ‒ 2013. ‒ Vol.23, № 3. ‒ P. 350-355.123. Eming S.A., Martin P., Tomic-Canic M. Wound repair andregeneration: mechanisms, signaling, and translation // Sci. Transl. Med. ‒ 2014. ‒Vol. 6, № 265. ‒ P. 265.124. Eppley B.L., Pietrzak W.S., Blanton M. Platelet-rich plasma: a reviewof biology and applications in plastic surgery // Plast. Reconstr. Surg.- 2006.- Vol.118. - P.
147–159.125. Esmat S., Hegazy R.A., Shalaby S. et al. Phototherapy andCombination Therapies for Vitiligo // Dermatol. Clin. ‒ 2017. ‒ Vol. 35, № 2. ‒ P.171-192.126. Esmat S., Abdel Halim D.M., Hegazy R.A. et al. Matrixmetalloproteinase in acral and non-acral vitiligo // Photodermatol PhotoimmunolPhotomed. - 2018. - Vol.34(3). - P.211-213.127.
Falabella R. Surgical approaches for stable vitiligo // Dermatol. Surg.‒ 2005. ‒ Vol. 31, № 10. ‒ P. 1277-1284.128. Feetham H.J., Chan J.L., Pandya A.G. Characterization of clinical113response in patients with vitiligo undergoing autologous epidermal punch grafting// Dermatol. Surg. ‒ 2012. ‒ Vol. 38, № 1. ‒ P. 14-19.129. FelstenL.M.,AlikhanA.,Petronic-RosicV.Vitiligo:acomprehensive overview Part II: treatment options and approach to treatment // J.Am.
Acad Dermatol. - 2011. - Vol.65. - P.493-514.130. Filardo G., Kon E., Della Villa S. et al. Use of platelet-rich plasma forthe treatment of refractory jumper's knee // Int. Orthop. ‒ 2010. ‒ Vol. 34, № 6. ‒P. 909-915.131. Filardo G., Kon E., Di Martino A. et al. Platelet-rich plasma vshyaluronic acid to treat knee degenerative pathology: study design and preliminaryresults of a randomized controlled trial // BMC Musculoskelet.
Disord. ‒ 2012. ‒Vol. 13. ‒ P. 229.132. Flad H.D., Brandt E. Platelet-derived chemokines: pathophysiologyand therapeutic aspects // Cell Mol. Life Sci. ‒ 2010. ‒ Vol. 67, № 14. ‒ P. 23632386.133. Fongers A., Wolkerstorfer A., Nieuweboer-Krobotova L. et al. Longterm results of 2-mm punch grafting in patients with vitiligo vulgaris andsegmental vitiligo: effect of disease activity // Br. J.
Dermatol. ‒ 2009. ‒ Vol. 161,№ 5. ‒ P. 1105-1111.134. Garg A.K. The use of platelet-rich plasma to enhance the success ofbone grafts around dental implants // Dent. Implantol. Update. ‒ 2000. ‒ Vol. 11,№ 3. ‒ P. 17-21.135. Garg S., Dosapaty N., Arora A.K. Laser Ablation of the RecipientArea With Platelet-Rich Plasma-Enriched Epidermal Suspension Transplant inVitiligo Surgery: A Pilot Study // Dermatol Surg. - 2019. - Vol.45(1).
- P.83-89.136. Gauthier Y., Benzekri L. Non-cultured epidermal suspension invitiligo: from laboratory to clinic // Indian J. Dermatol. Venereol. Leprol. ‒ 2012. ‒Vol. 78, № 1. ‒ P. 59-63.137. Gawkrodger D.J., Ormerod A.D., Shaw L. et al. Guideline for thediagnosis and management of vitiligo // Br. J. Dermatol. ‒ 2008. ‒ Vol. 159, № 5.114‒ P.
1051-1076.138. Ghia D., Mulekar S. Handbook of vitiligo: basic science and clinicalmanagement. – London: JP Medical Publishers, 2015. – 202 p.139. Gibbons N.C., Wood J.M., Rokos H., Schallreuter K.U. Computersimulation of native epidermal enzyme structures in the presence and absence ofhydrogen peroxide (H2O2): potential and pitfalls // J. Invest. Dermatol. ‒ 2006. ‒Vol. 126, № 12. ‒ P. 2576-2582.140.
Gill L., Zarbo A., Isedeh P. et al. Comorbid autoimmune diseases inpatients with vitiligo: A cross-sectional study // J. Am. Acad. Dermatol. ‒ 2016. ‒Vol. 74, № 2. ‒ P. 295-302.141. Glassman S.J. Vitiligo, reactive oxygen species and T-cells // Clin. Sci(Lond). - 2011.
- Vol.120 (3). - P.99-120.142. Gleissner C.A., Shaked I., Little K.M., Ley K. CXC chemokine ligand4 induces a unique transcriptome in monocyte-derived macrophages // J. Immunol.‒ 2010. ‒ Vol. 184, № 9. ‒ P. 4810-4818.143. Gokhale B.B., Parakh A.P. Cyclophosphamide in vitiligo // Indian J.Dermatol. ‒ 1983. ‒ Vol.
28, № 1. ‒ P. 7-10.144. Gokhale B.B., Mehta L.N. Histopathology of vitiliginous skin // Int. J.Dermatol. ‒ 1983. ‒ Vol. 22, № 8. ‒ P. 477-80.145. Gou D., Currimbhoy S., Pandya A.G. Suction blister grafting forvitiligo: efficacy and clinical predictive factors // Dermatol. Surg. ‒ 2015.
‒ Vol.41, № 5. ‒ P. 633-639.146. Guerra L., Primavera G., Raskovic D. et al. Erbium:YAG laser andcultured epidermis in the surgical therapy of stable vitiligo // Arch. Dermatol. ‒2003. ‒ Vol. 139, № 10. ‒ P. 1303-1310.147. Gumina S., Campagna V., Ferrazza G. et al. Use of platelet-leukocytemembrane in arthroscopic repair of large rotator cuff tears: a prospectiverandomized study // J. Bone Joint Surg. Am. ‒ 2012. ‒ Vol. 94, № 15.
‒ P. 13451352.148. Gupta S., Kumar B. Epidermal grafting in vitiligo: influence of age,115site of lesion, and type of disease on outcome // J. Am. Acad. Dermatol. ‒ 2003. ‒Vol. 49, № 1. ‒ P. 99-104.149. Gupta S., Shroff S., Gupta S. Modified technique of suction blisteringfor epidermal grafting in vitiligo // Int. J. Dermatol. ‒ 1999.
‒ Vol. 38, № 4. ‒ P.306-309.150. Halpern S.M., Anstey A.V., Dawe R.S. et al. Guidelines for topicalPUVA: a report of a workshop of the British photodermatology group // Br. J.Dermatol. ‒ 2000. ‒ Vol. 142, № 1. ‒ P. 22-31.151. Handa S., Dogra S. Epidemiology of childhood vitiligo: a study of 625patients from north India // Pediatr. Dermatol. ‒ 2003.
‒ Vol. 20, № 3. ‒ P. 207210.152. Harris J.E. Chemical-Induced Vitiligo // Dermatol. Clin. ‒ 2017. ‒Vol. 35, № 2. ‒ P. 151-161.153. Harris J.E. Cellular stress and innate inflammation in organ-specificautoimmunity: lessons learned from vitiligo // Immunol. Rev. ‒ 2016. ‒ Vol. 269,№ 1. ‒ P. 11-25.154. Harris J.E., Harris T.H., Weninger W. et al. A mouse model of vitiligowith focused epidermal depigmentation requires IFN-gamma for autoreactiveCD8(+) T-cell accumulation in the skin // J.
Invest. Dermatol. ‒ 2012. ‒ Vol. 132,№ 7. ‒ P. 1869-1876.155. Hirobe T., Hasegawa K., Furuya R. et al. Effects of fibroblast-derivedfactors on the proliferation and differentiation of human melanocytes in culture // J.Dermatol. Sci. - 2013.- Vol.71(1). - P.45-57.156. Hirobe T. Role of keratinocyte-derived factors involved in regulatingthe proliferation and differentiation of mammalian epidermal melanocytes //Pigment Cell Res. - 2005.- Vol.18(1).- P.2-12.157.
Ho N., Pope E., Weinstein M. et al. A double-blind, randomized,placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05%in childhood vitiligo // Br. J. Dermatol. ‒ 2011. ‒ Vol. 165, № 3. ‒ P. 626-632.158. Hossain C., Porto D.A., Hamzavi I., Lim H.W. Camouflaging Agents116for Vitiligo Patients // J. Drugs. Dermatol.
‒ 2016. ‒ Vol. 15, № 4. ‒ P. 384-387.159. Hsu W.K., Mishra A., Rodeo S.R. et al. Platelet-rich plasma inorthopaedic applications: evidence-based recommendations for treatment // J. Am.Acad. Orthop. Surg. ‒ 2013. ‒ Vol. 21, № 12. ‒ P. 739-748.160. Huang C.L., Nordlund J.J., Boissy R. Vitiligo: a manifestation ofapoptosis? // Am. J. Clin. Dermatol.- 2002. - Vol. 3. - P. 301–308.161. Huggins R.H., Henderson M.D., Mulekar S.V. et al.
Melanocytekeratinocyte transplantation procedure in the treatment of vitiligo: the experienceof an academic medical center in the United States // J. Am. Acad. Dermatol. ‒2012. ‒ Vol. 66, № 5. ‒ P. 785-793.162. Hyter S., Coleman D.J., Ganguli-Indra G. et al. Endothelin-1 is atranscriptional target of p53 in epidermal keratinocytes and regulates ultravioletinduced melanocyte homeostasis // Pigment Cell Melanoma Res.
-2013.-Vol.26(2). - P.247-258.163. Ibrahim Z.A., El-Ashmawy A.A., El-Tatawy R.A., Sallam F.A. Theeffect of platelet-rich plasma on the outcome of short-term narrowband-ultravioletB phototherapy in the treatment of vitiligo: a pilot study // J. Cosmet. Dermatol. ‒2016. ‒ Vol. 15, №2. ‒ P. 108-116.164. Itoi S., Tanemura A., Kotobuki Y. et al. Coexistence of Langerhanscells activation and immune cells infiltration in progressive nonsegmental vitiligo// J. Dermatol.
Sci. ‒ 2014. ‒ Vol. 73, № 1. ‒ P. 83-85.165. Jain D., Misra R., Kumar A. et al. Levels of malondialdehyde andantioxidants in the blood of patients with vitiligo of age group 11-20 years // IndianJ. Physiol. Pharmacol. - 2008. - Vol.52 (3). - P.297-301.166. Jedlitschky G., Tirschmann K., Lubenow L.E. et al. The nucleotidetransporter MRP4 (ABCC4) is highly expressed in human platelets and present indense granules, indicating a role in mediator storage // Blood.
‒ 2004. ‒ Vol. 104,№ 12. ‒ P. 3603-3610.167. Jian Z., Li K., Liu L. et al. Heme oxygenase-1 protects humanmelanocytes from H2O2-induced oxidative stress via the Nrf2-ARE pathway // J.117Invest. Dermatol. - 2011. - Vol.131(7). - P.1420-1427.168. Jian Z., Li K., Song P. et al. Impaired activation of the Nrf2-AREsignaling pathway undermines H2O2-induced oxidative stress response: a possiblemechanism for melanocyte degeneration in vitiligo // J. Invest.
Dermatol. - 2014. Vol.134 (8). - P.2221-2230.169. Jin Y., Birlea S.A., Fain P.R. et al. Genome-wide association analysesidentify 13 new susceptibility loci for generalized vitiligo // Nat. Genet. ‒ 2012. ‒Vol. 44, № 6. ‒ P. 676-680.170. Jung H., Chung H., Chang S.E. et al. FK506 regulates pigmentationby maturing the melanosome and facilitating their transfer to keratinocytes //Pigment Cell. Melanoma. Res. ‒ 2016. ‒ Vol. 29, № 2. ‒ P. 199-209.171.
Jung H., Oh E.S. FK506 positively regulates the migratory potential ofmelanocyte-derived cells by enhancing syndecan-2 expression // Pigment Cell.Melanoma. Res. ‒ 2016. ‒ Vol. 29, № 4. ‒ P. 434-443.172. Kadry M., Tawfik A., Abdallah N. et al. Platelet-rich plasma versuscombined fractional carbon dioxide laser with platelet-rich plasma in the treatmentof vitiligo: a comparative study // Clin Cosmet Investig Dermatol.- 2018. -Vol.11. - P.551-559.173. Kahn A.M., Cohen M.J.
Vitiligo: treatment by dermabrasion andepithelial sheet grafting // J. Am. Acad. Dermatol. ‒ 1995. ‒ Vol. 33, № 4. ‒ P.646-648.174. Kahn A.M., Cohen M.J. Repigmentation in vitiligo patients.Melanocyte transfer via ultra-thin grafts // Dermatol. Surg. ‒ 1998. ‒ Vol. 24, № 3.‒ P. 365-367.175. Kandil E. Treatment of localized vitiligo with intradermal injectionsof triamcinolone acetonide // Dermatologica.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
